Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

Citi analysts have advised investors to cash out on Moderna, suggesting that the stock's previous gains of over 600% may be unsustainable. They argue that current revenue and profit forecasts don't support Moderna's inflated share price. This move highlights concerns about overvaluation in the biotech sector, especially for companies riding the vaccine wave. Investors should consider these implications carefully as Moderna's stock performance could shift in response to broader market trends and sector dynamics.